I think one clue from the SNO announcement that it might be at least a partially successful trial is how they put Autologous Dendritic therapy on trial for survival in the announcement for presentation. Basically they made the Presentation sound like the trial would be the final arbiter on whether Or not tumor lysate pulsed autologous DC therapy extends survival in GBM. That’s a pretty bold objective.